<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156443">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01945892</url>
  </required_header>
  <id_info>
    <org_study_id>MAF/ISS/OPH/RET/011</org_study_id>
    <nct_id>NCT01945892</nct_id>
  </id_info>
  <brief_title>Dexamethasone-Implant for the Treatment of Macula Edema Due to Irvine Gass Syndrome</brief_title>
  <official_title>Ozurdex as an Treatment Option for Macula Edema Due to Irvine Gass Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To analyze macula edema formation after cataract surgery called Irvine-Gass-Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      20 to 25 patients suffering from Irvine Gass Syndrom should be monitored for at least six
      months, controlled monthly. In all cases best corrected visual acuity, Spectralis-OCT
      (volume thickness scan), fundus photography (Optomap), intraocular pressure, slitlamp
      assessment and indirect ophthalmoscopy should be performed on every visit. Fluorescein
      angiography should be performed at baseline and after 3 and 6 months.

      Inclusion criteria:

      Patients older than 18 years who develop macula edema secondary to cataract surgery.

      - Consent agreement - Patients should be informed that it is possible to get an active
      medication (Ozurdex implant) as an &quot;on label&quot; indication from the health insurance company
      if the diagnosis is accepted as an intraocular inflammation form of &quot;Uveitis posterior&quot;.

      Exclusion criteria:

      Visual acuity worse than 20/400, known history of glaucoma and steroid response, any macular
      disease interfering with visual acuity (DME, AMD, etc.), history of vitrectomy, use of
      systemic, periocular, or intraocular corticosteroids within 30 days.

      Outcome:

        -  BCVA

        -  Patients suffering from diabetes mellitus should be evaluated also separately.

        -  Change in central retinal thickness using optical coherence tomography (OCT)

        -  Secondary parameters (elevated IOP, retinal detachments, vitreous hemorrhage,
           endophthalmitis rates)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Best corrected visual acuity and visual acuity gain after 6 and 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal Thickness</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Retinal thickness measured by OCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Intraocular pressure using Goldmann applanation tonometer</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">23</enrollment>
  <condition>Macular Edema</condition>
  <condition>Visual Acuity</condition>
  <arm_group>
    <arm_group_label>Irvine Gass Syndrome</arm_group_label>
    <description>Patients older than 18 years who develop macula edema secondary to cataract surgery.
Group may receive intravitreal Ozurdex medication in case of persistent macular edema.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozurdex</intervention_name>
    <description>- Consent agreement - Patients should be informed that it is possible to get an active medication (Ozurdex implant) as an &quot;on label&quot; indication from the health insurance company if the diagnosis is accepted as an intraocular inflammation form of &quot;Uveitis posterior&quot;.</description>
    <arm_group_label>Irvine Gass Syndrome</arm_group_label>
    <other_name>Dexamethasone-implant</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients older than 18 years.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients older than 18 years who develop macula edema secondary to cataract surgery

        Exclusion Criteria:

        Visual acuity worse than 20/400, known history of glaucoma and steroid response, any
        macular disease interfering with visual acuity (DME, AMD, etc.), history of vitrectomy,
        use of systemic, periocular, or intraocular corticosteroids within 30 days.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang J Mayer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LMU Munich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos Haritoglou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LMU Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Ophthalmology, LMU Munich</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 18, 2013</lastchanged_date>
  <firstreceived_date>September 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Wolfgang Mayer</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>macular edema, irvine gass syndrome, ozurdex</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
